**Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide**

**ISHTIY AQ AHMAD NAJAR and RAKESH KAMAL JOHRI**

*J. Biosci.* 39(1), March 2014, 139–144, © Indian Academy of Sciences

**Supplementary material**

**Supplementary table 1.** Documented clinical pharmacokinetics of etoposide

<table>
<thead>
<tr>
<th>Year</th>
<th>Study</th>
<th>References</th>
</tr>
</thead>
</table>


2000 Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day Aydiner A, Koyuncu H, Tas F, Topuz E and Disci R 2000 Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. *Int. J. Clin. Pharmacol. Res.* 20 21–30


1998 Pharmacokinetic aspects of oral administration of etoposide


1998 Population pharmacokinetics of total and unbound etoposide


1998 Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small-cell lung cancer


1996 Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study


1996 Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer


1997 Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi’s sarcoma with no prior exposure to cytotoxic therapy


1997 Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy


1997 Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide


1997 Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma


1996 Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study


1996 Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer


1996 Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients


1995 Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small-cell lung cancer


1995 Review of current clinical experience with prolonged (oral) etoposide in cancer treatment


1995 Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumours

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>